Researchers using commercial SNP genotyping arrays should be wary of using their results to make predictions about an individual's genetic risk of developing certain diseases, according to a new study.

The study, from scientists at Stanford University, found that risk predictions derived from next-generation sequencing differ substantially from those obtained from genotyping arrays for several non-monogenic diseases. At the same time, high-density genotyping arrays may give results that are identical with sequencing results for many diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.